Investment Rating - The investment rating for the company is "Accumulate-A" with a target price of 22 CNY per share, maintaining the rating [1][6]. Core Views - The company reported a significant decline in revenue and net profit for the first half of 2024, with revenue at 7.237 billion CNY, down 27.31% year-on-year, and net profit at 2.212 billion CNY, down 56.60% year-on-year [1][2]. - The potassium and lithium salt businesses are the main profit contributors, although both experienced a decline in revenue and gross margin [2][3]. - The company maintains a competitive advantage in lithium extraction costs and has seen growth in both potassium and lithium production and sales [3][5]. Financial Performance - For H1 2024, the total revenue from potassium and lithium salt was 5.338 billion CNY and 1.683 billion CNY, respectively, accounting for 73.76% and 23.26% of total revenue [2]. - The gross profit for potassium and lithium salt was 2.857 billion CNY and 1.012 billion CNY, with gross margins of 53.52% and 60.16%, reflecting a year-on-year decline of 19.39 percentage points and 22.86 percentage points, respectively [2]. - The company produced 18,916 tons of lithium carbonate in H1 2024, a year-on-year increase of 34.20%, with sales reaching 20,242 tons, also up 34.94% year-on-year [3]. Future Outlook - The company expects revenues of 15.706 billion CNY, 18.959 billion CNY, and 21.635 billion CNY for 2024, 2025, and 2026, respectively, with net profits projected at 4.760 billion CNY, 6.454 billion CNY, and 7.857 billion CNY [6][8]. - The company plans to increase its lithium carbonate production capacity to 40,000 tons in 2024, further solidifying its leading position in the lithium extraction sector [5][6].

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 74.4 CNY, while the current stock price is 42.09 CNY [1]. Core Insights - The company reported a revenue of 1.295 billion CNY in the first half of 2024, representing a year-on-year increase of 28.50%. The net profit attributable to shareholders was 404 million CNY, up 16.79% year-on-year [1][2]. - The company has a strong growth trajectory in its core business, particularly in the life sciences sector, which is experiencing rapid growth [2][7]. - The company plans to build an additional 20,000 tons of high-end material capacity to meet the increasing demand in high-value applications [4]. Summary by Sections Financial Performance - In the first half of 2024, the company achieved a revenue of 1.295 billion CNY, with a net profit of 404 million CNY, reflecting a year-on-year growth of 28.50% and 16.79% respectively [1][2]. - The second quarter of 2024 saw revenues of 664 million CNY, a 30.98% increase year-on-year, and a net profit of 235 million CNY, up 10.75% year-on-year [1]. Business Segments - The revenue from the lithium extraction business was 99 million CNY, a year-on-year increase of 8%. The core business revenue, excluding lithium projects, was 1.196 billion CNY, up 31% year-on-year, accounting for 92.36% of total revenue [2]. - The adsorption materials segment generated 974 million CNY in revenue, representing 82% of the total revenue, while system devices contributed 190 million CNY, accounting for 16% [2]. Growth Prospects - The company plans to enhance its production capacity with the construction of a new facility for high-end materials, targeting applications in ultra-pure water and food sectors [4]. - The company has completed over 15 lithium extraction projects, with a total capacity of nearly 100,000 tons, and six projects are already operational [5][6]. Market Expansion - The overseas sales revenue reached 352 million CNY, marking a 56% year-on-year increase, indicating a growing market penetration [2]. - The life sciences segment's revenue from adsorption materials was 285 million CNY, up 33% year-on-year, driven by strong market performance of GLP-1 peptide drugs [7]. Future Projections - The company forecasts revenues of 2.967 billion CNY, 3.652 billion CNY, and 4.640 billion CNY for 2024, 2025, and 2026 respectively, with corresponding net profits of 921.8 million CNY, 1.173 billion CNY, and 1.475 billion CNY [8].

Investment Rating - The investment rating for Huaxin Cement is maintained as "Buy - A" with a target price of 12.74 CNY [4]. Core Views - The report highlights that domestic cement operations are under pressure, while overseas cement sales and prices are rising. The aggregate business is performing well [2][3]. - In H1 2024, the company achieved revenue of 16.237 billion CNY, a year-on-year increase of 2.56%, but the net profit attributable to shareholders decreased by 38.74% to 731 million CNY [2][3]. - The report anticipates marginal improvement in domestic cement demand as the real estate sector stabilizes, alongside supply-side measures that may lead to price and profit recovery [6]. Summary by Sections Financial Performance - In H1 2024, Huaxin Cement's revenue was 16.237 billion CNY, with Q1 and Q2 growth rates of 6.87% and -0.54% respectively. Domestic revenue fell by 4.2%, while overseas revenue surged by 55.46% [2]. - The cement business generated 8.666 billion CNY in revenue, down 11.25% year-on-year, with sales volume at approximately 28.484 million tons, a decrease of 4.90% [2][3]. - The gross profit margin for the cement segment was 20.71%, down 2.1 percentage points year-on-year, while the overall gross margin was 23.65% [3]. Overseas Operations - The overseas cement business generated 3.578 billion CNY in revenue, a year-on-year increase of 55.41%, accounting for about 22.04% of total revenue [3][6]. - New production lines in Mozambique and Malawi are expected to contribute significantly to future revenue growth, with an anticipated increase in clinker production capacity of approximately 3 million tons per year [3][6]. Non-Cement Business - The aggregate business showed strong growth, with revenue reaching 2.962 billion CNY, up 36.96% year-on-year, and a gross margin of 47.41% [6]. - The concrete business also performed well, with revenue of 3.943 billion CNY, a year-on-year increase of 24.21% [6]. Future Outlook - The report projects overall revenue for 2024-2026 to be 34.981 billion CNY, 36.825 billion CNY, and 38.298 billion CNY, with respective year-on-year growth rates of 3.62%, 5.27%, and 4.00% [6]. - Net profit forecasts for the same period are 2.039 billion CNY, 2.322 billion CNY, and 2.572 billion CNY, with growth rates of 26.18%, 13.90%, and 10.76% respectively [6].

本报告仅供 Choice 东方财富 使用，请勿传阅。 2024 年 09 月 05 日 欧派家居(603833.SH) H1 业绩短期承压，期待需求稳健修复 事件：欧派家居发布 2024 年半年报。2024H1 公司实现营业收 入 85.83 亿元，同比下降 12.81%；归母净利润 9.90 亿元，同比 下降 12.61%；扣非后归母净利润 7.76 亿元，同比下降 27.54%。 其中，2024Q2 公司实现营业收入 49.62 亿元，同比下降 20.91%； 归母净利润 7.72 亿元，同比下降 21.26%；扣非后归母净利润 6.34 亿元，同比下降 32.72%。 卫浴及直营渠道逆势增长，推进营销体系大家居转型 分品类看，24H1 公司衣柜及配套家具产品、橱柜、卫浴、木门、其他 分别实现收入 44.19/25.57/5.03/4.97/4.25 亿元，同比分别18.63%/-16.76%/+9.29%/-13.61%/+234.08%。尽管受房地产红利消 退、消费者偏好变化、消费驱动力不足、行业竞争加剧等因素影响， 卫浴和其他品类营收仍保持稳步增长。 分渠道看，24H1 直营店/经销店/大宗业务/其 ...

行业专题 2024 年 09 月 05 日 工程机械Ⅱ 行业筑底复苏，看好内外需同步改善 工程机械板块样本选择：我们选取三一重工、中联重科、徐工 机械、柳工、山推股份、山河智能、厦工股份、建设机械、恒立 液压、艾迪精密、长龄液压、浙江鼎力、诺力股份、安徽合力、 杭叉集团 15 家公司作为 A 股机械行业工程机械板块的研究样本。 工程机械 2024 年半年报经营总结：从统计样本表观数据来看， ①板块弹性强于大盘：年初至 8 月 30 日沪深 300 涨幅 4.62%，年 初至 5 月 16 日板块涨幅 24.22%，主要系业绩兑现、内需复苏、 更新政策催化，随后涨幅受出口避险情绪影响 8 月 30 日回调至 1.94%；②出口驱动收入增长：2024 年 H1，板块收入 1727.4 亿 元，同比+1.54%，其中板块海外收入同比+13.5%，占比 49.38%（建 设机械、长龄液压、浙江鼎力、杭叉集团均无相关披露，在此剔 除）；③成本支撑利润弹性：2024 年 H1，板块归母净利润 150.13 亿元，同比+9.37%，弹性强于收入系原料成本低位、市场结构优 化、经营效率提升等因素共同促进；④费用管控成效显现： ...

本报告仅供 Choice 东方财富 使用，请勿传阅。 2024 年 09 月 04 日 绿的谐波(688017.SH) 盈利端承压，机电一体化新产品布局中 事件： 绿的谐波发布 2024 年半年报，2024H1 公司实现营业收入 1.72 亿元， 同比增长 0.49%；归母净利润 0.37 亿元，同比减少 27.69%。2024Q2 单季实现营业收入 0.9 亿元，同比增长 8.96%；归母净利润 0.17 亿 元，同比减少 36.51%。 下游智能机器人需求增速放缓，竞争加剧影响盈利。2024H1， 公司营业收入小幅增长，Q2 季度收入增幅有所复苏，公司产品主 要挂钩下游工业机器人景气度，2024H1 我国工业机器人市场销量 约 14 万台，增速放缓，同增 5%；产量为 28.32 万套，同增 9.6%。 整体市场需求仍有较大压力，公司产品销售保持平稳。随 3C、半 导体等行业需求逐步有所回暖以及机器人密度提升，谐波减速器 产品需求有望稳步增长。盈利端，①竞争加剧，毛利率有所下降。 2024H1，公司综合毛利率分别为 40.39%，同比下降 1.92pct，主 要系谐波产品需求疲软下市场价格下降所致，此外亦 ...

Investment Rating - The investment rating for the company is "Buy-A" with a target price of HKD 5.27 over the next six months [1][6]. Core Insights - The company, VESYNC, reported a strong revenue growth of 7.0% year-over-year (YoY) in H1 2024, achieving a revenue of USD 300 million and a net profit of USD 40 million, which is a 37.5% YoY increase [6][8]. - The company is expanding its product range and actively developing offline sales channels while entering European and Asian markets, which is expected to drive rapid revenue growth [6][8]. - VESYNC maintains a leading position in the small appliance market on Amazon in the U.S. and has established a long-term partnership with Amazon [6][8]. Financial Summary - Revenue projections for the company are as follows: USD 490.4 million in 2022, USD 585.5 million in 2023, USD 630.9 million in 2024, USD 689.6 million in 2025, and USD 752.0 million in 2026 [4][9]. - Net profit is expected to recover from a loss of USD 16.3 million in 2022 to USD 96.9 million in 2024, reaching USD 116.8 million by 2026 [4][9]. - Earnings per share (EPS) are projected to increase from -0.01 in 2022 to 0.10 in 2026 [4][9]. - The price-to-earnings (P/E) ratio is forecasted to improve from -37.1 in 2022 to 5.2 in 2026, indicating a significant recovery in profitability [5][9]. - The net profit margin is expected to rise from -3.3% in 2022 to 15.5% in 2026, reflecting improved operational efficiency [5][9]. Market Performance - The company's stock price as of September 4, 2024, is HKD 4.11, with a 12-month price range of HKD 2.81 to HKD 5.75 [1][6]. - The relative returns over different periods are as follows: 5.0% over 1 month, -9.0% over 3 months, and 30.7% over 12 months [2][6].

本报告仅供 Choice 东方财富 使用，请勿传阅。 公司快报 2024 年 09 月 04 日 美凯龙(601828.SH) 证券研究报告 专业市场经营Ⅲ 投资评级 增持-A 下调评级 12 个月目标价 2.75 元 股价 (2024-09-03) 2.23 元 交易数据 总市值(百万元) 9,711.05 流通市值(百万元) 8,057.99 总股本(百万股) 4,354.73 流通股本(百万股) 3,613.45 12 个月价格区间 2.19/4.87 元 升幅% 1M 3M 12M 相对收益 -8.6 -17.1 -39.6 绝对收益 -11.9 -25.9 -53.2 罗乾生 分析师 liuxf3@essence.com.cn 相关报告 经营短期有所承压，期待建 发协同发展 2024-05-06 自营商场稳健发展，费用管 控成效显著 2023-04-05 建发股份拟入主美凯龙，卖 场龙头有望焕发新机 2023-01-09 租金减免勇担社会责任，期 间费用管控成效显现 2022-11-02 主业营收呈现相对韧性，业绩受非经影 响拖累 事件：美凯龙发布2024年半年报。2024H1公司实现营业收入42. ...

Investment Rating - The report maintains an "Overweight-A" rating for Ningbo Yunsheng with a 6-month target price of 7.7 yuan, implying a 38.5x forward P/E for 2024 [4][8] Core Views - The company's performance improved significantly in Q2 2024, with revenue of 1.28 billion yuan (+2.01% YoY, +24.81% QoQ) and net profit of 39 million yuan, turning profitable both YoY and QoQ [1] - Rare earth prices stabilized in Q2 2024, with praseodymium-neodymium oxide prices rebounding 14% in Q3 to 415,000 yuan/ton, which is expected to boost downstream procurement and further improve the company's performance [2] - The company achieved a 20.4% market share in China's new energy vehicle main drive motor market in H1 2024, with 840,000 sets of main drive motors [3] - Revenue from consumer electronics grew 22% YoY in H1 2024, driven by AI technology applications and inventory replenishment [3] Financial Performance - H1 2024 revenue was 2.31 billion yuan (-14.1% YoY), with net profit of 39 million yuan, turning profitable YoY [1] - NdFeB product revenue was 2.10 billion yuan (-12% YoY) in H1 2024, accounting for 91.2% of total revenue [2] - Revenue breakdown by segment in H1 2024: new energy vehicles 1.00 billion yuan (+8% YoY), consumer electronics 622 million yuan (+22% YoY), industrial and others 480 million yuan (-49% YoY) [2] Market Position - The company holds a leading position in the new energy vehicle motor market with a 20.4% market share in H1 2024 [3] - In consumer electronics, the company expanded its order share among strategic customers, maintaining competitive advantages [3] Future Projections - Revenue is expected to grow to 4.81 billion yuan in 2024, 6.00 billion yuan in 2025, and 8.40 billion yuan in 2026 [4] - Net profit is projected to reach 217 million yuan in 2024, 356 million yuan in 2025, and 522 million yuan in 2026 [4]

Investment Rating - The report maintains a "Buy-A" investment rating for the company, with a 6-month target price of 25.40 CNY per share [5][6]. Core Insights - The company achieved a revenue of 11.762 billion CNY in H1 2024, representing a year-on-year growth of 9.86%. The net profit attributable to shareholders after deducting non-recurring items was 786 million CNY, up 15.77% year-on-year [2][5]. - The growth in profits is attributed to both organic and external growth from store expansion, as well as improved management efficiency [2][3]. - The company continues to focus on a "regional focus and steady expansion" strategy, with a total of 14,736 stores as of H1 2024, marking a 27.25% increase compared to H1 2023 [3]. - The overall gross margin for H1 2024 was 40.05%, slightly up by 0.06 percentage points from the previous year, indicating stable profitability [4]. Summary by Sections Revenue and Profit Growth - In H1 2024, the company reported revenues of 117.62 billion CNY, with retail and wholesale segments contributing 103.98 billion CNY (+8.32%) and 9.97 billion CNY (+20.91%) respectively [2][5]. - The net profit attributable to shareholders after non-recurring items was 786 million CNY, reflecting a 15.77% increase year-on-year [2][5]. Store Expansion Strategy - The company has been actively expanding its store network, with 842 new self-built stores, 293 acquired stores, and 440 new franchise stores added in H1 2024 [3]. - The total number of stores reached 14,736, including 3,426 franchise stores, demonstrating a robust growth strategy [3]. Profitability and Management Efficiency - The company's gross margin stood at 40.05% in H1 2024, with specific margins for various product categories: 34.85% for Western and Chinese medicines, 48.74% for traditional Chinese medicine, and 51.10% for non-pharmaceutical products [4]. - Management efficiency improved, as evidenced by a decrease in sales and management expense ratios by 0.15 and 0.20 percentage points respectively [4].